Analytical instruments, not models, may be China's toughest biotech chokepoint

PAstynome · x · 2026-11-20

PAstynome argues China's real chokepoint is analytical instruments — a market dominated by Agilent, BD, and Thermo-Fisher with Shimadzu as the only major non-US supplier, a dependency as tough as semiconductor fab tools. The quoted post counters that China's biotech ecosystem has no glaring holes: favorable regulation, automated labs at parity, and speed advantages in clinical trials and approvals that outweigh any in silico gains — and it's not about labor costs. A useful snapshot of the instruments-vs-trials debate in US–China biotech competition.

Original post →

More from Infra

Infra channel →